Insmed reports fourth-quarter and full-year 2023 financial results and provides business update

—topline data from the phase 3 aspen trial of brensocatib in adult patients with bronchiectasis remain on track to read out in the latter part of second-quarter 2024— —enrollment in the phase 2 study of tpip in patients with ph-ild completed in november 2023; topline data expected in second-quarter 2024 ahead of the aspen readout— —company ends 2023 with $780 million of cash, cash equivalents, and marketable securities, providing runway beyond the expected aspen readout— — arikayce® (amikacin liposome inhalation suspension) total revenue of $83.7 million for fourth-quarter and $305.2 million for full-year 2023, reflecting 24% annual growth and exceeding the upper end of full-year 2023 guidance range— —company reiterates sales guidance for 2024 global arikayce revenues in the range of $340 million to $360 million, reflecting double-digit growth compared to 2023— bridgewater, n.j. , feb. 22, 2024 /prnewswire/ -- insmed incorporated (nasdaq:insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended december 31, 2023 and provided a business update.
INSM Ratings Summary
INSM Quant Ranking